LivaNova PLC $LIVN Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 168.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,125 shares of the company’s stock after purchasing an additional 17,007 shares during the quarter. Envestnet Asset Management Inc.’s holdings in LivaNova were worth $1,421,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LIVN. Allianz Asset Management GmbH bought a new position in shares of LivaNova in the 3rd quarter worth about $7,687,000. UMB Bank n.a. raised its stake in LivaNova by 63.0% during the third quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after acquiring an additional 306 shares during the period. Arizona State Retirement System lifted its holdings in LivaNova by 1.7% in the third quarter. Arizona State Retirement System now owns 16,129 shares of the company’s stock worth $845,000 after acquiring an additional 274 shares during the last quarter. New York State Common Retirement Fund boosted its stake in LivaNova by 107.5% in the third quarter. New York State Common Retirement Fund now owns 180,008 shares of the company’s stock valued at $9,429,000 after acquiring an additional 93,267 shares during the period. Finally, Federated Hermes Inc. boosted its stake in LivaNova by 1.6% in the third quarter. Federated Hermes Inc. now owns 131,965 shares of the company’s stock valued at $6,912,000 after acquiring an additional 2,099 shares during the period. Institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $70.60 on Monday. The stock has a market cap of $3.86 billion, a P/E ratio of -15.83 and a beta of 0.92. The firm’s 50-day simple moving average is $64.74 and its 200 day simple moving average is $59.14. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $71.92. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.80 by $0.06. The firm had revenue of $360.86 million for the quarter, compared to analysts’ expectations of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. LivaNova’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the company earned $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities analysts expect that LivaNova PLC will post 2.85 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LIVN. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Robert W. Baird set a $75.00 target price on LivaNova in a research note on Tuesday, December 16th. Mizuho boosted their price target on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.78.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.